PEARCE IP
Our Capabilities
Pearce IP is a boutique firm offering intellectual property specialist lawyers, patent attorneys and trade mark attorneys, to the pharmaceutical, biopharmaceutical and life sciences industries.
With staff based in Australia and New Zealand, we coordinate and execute local and multi-jurisdictional IP litigation strategies, provide IP/legal support for regional and global business development activities and licensing deals, and prosecute patent and trade mark applications around the world.
Since its establishment in 2017 boutique Pearce IP has dominated in the area of pharmaceutical patents. Thanks to its deep bench of talented professionals, any life sciences brief is dispatched with alacrity and poise.
IP SPECIALIST LAWYERS – PATENT ATTORNEYS – TRADE MARK ATTORNEYS
Our Leaders
Naomi Pearce
CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (AU, NZ)
Adele Chadwick
Executive, Deputy CEO & Head of Talent
Paul Johns
Executive, Lawyer (Head of Litigation - New Zealand)
Kimberley Evans
Executive, Lawyer & Trade Mark Attorney (Head of Trade Marks)
Chris Coates (Maj Ret)
Executive, Finance
Julie Ballance
Executive, Patent Attorney and Trade Mark Practitioner (AU, NZ), Lawyer (NZ) & Notary (NZ)
Sally Paterson
Executive, Patent & Trade Mark Attorney (AU, NZ), Lawyer (NZ)
Helen Macpherson
Executive, Lawyer (Head of Litigation - Australia)
PEARCE IP BLOG
Read our latest updates & insights
DRUG ADVERTISING IN NEW ZEALAND – NZ allows advertising of unapproved drugs… soon
A new development in New Zealand will provide an option for a faster route to judgment in patent and other intellectual property litigation. From 1 October 2025, a Commercial…
Pearce IP BioBlast® for the week ending 11 July 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®.  Significant biosimilar activities for the week ending 11 July are set out below…
Pearce IP BioBlast® for the week ending 4 July 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®.  Significant biosimilar activities for the week ending 4 July are set out below…
Product specific reports based on extracts from our BioBlast® database
adalimumab | Humira® | AbbVie
aflibercept | Eylea® | Regeneron
bevacizumab | Avastin® | Roche/Genentech
cetuximab | Erbitux® | BMS/Merck
daratumumab | Darzalex® | J&J
darbepoetin | Aranesp® | Amgen
denosumab | Prolia®/Xgeva® | Amgen
dupilumab | Dupixent® | Sanofi-Aventis
eculizumab | Soliris® | Alexion
filgrastim (GCSF) | Neupogen® | Amgen
golimumab | Simponi® | Janssen
guselkumab | Tremfya® | Janssen
infliximab | Remicade® | Johnson & Johnson
ixekizumab | Taltz® | Eli Lilly
lecanemab | Leqembi® | Eisai/Biogen
liraglutide | Victoza® /Saxenda® | Novo Nordisk
natalizumab | Tysabri® | Biogen/Elan
olaparib | Lynparza® | AstraZeneca/Merck
omalizumab | Xolair® | Genentech / Novartis
pegfilgrastim | Neulasta® | Amgen
pembrolizumab | Keytruda® | MSD
pertuzumab | Perjeta® | Roche
ranibizumab | Lucentis® | Genentech
regdanvimab | Regkirona® | Celltrion
risankizumab | Skyrizi® | AbbVie
rituximab | Rituxan®/MabThera® | Genentech/Biogen
secukinumab | Cosentyx® | Novartis
semaglutide | Wegovy®/Ozempic® | Novo Nordisk
tocilizumab | Actemra® | Roche
trastuzumab | Herceptin® | Roche/Genentech
ustekinumab | Stelara® | Johnson & Johnson/Janssen
OUR VISION
By 2027, be the premier life sciences IP practice in
Australia and New Zealand.
AWARD WINNING IP SPECIALISTS LAWYERS - PATENT ATTORNEYS - TRADE MARK ATTORNEYS
Awards
2024 IAM Strategy 300
Australasian Lawyer
MIP Stars
IAM Patent 1000 2024
Legal 500 2024
